GlobeNewswire

Barloworld Equipment Innovates its Service with Librestream's Onsight

Dela

Librestream's Onsight platform brings expert remote capability to Barloworld Equipment

WINNIPEG, Manitoba, July 25, 2018 (GLOBE NEWSWIRE) -- Barloworld Equipment, southern Africa's leading Caterpillar dealer, has a reputation for excellence. The company is relentless in pursuit of its mission to deliver innovative solutions for exceptional customer performance through its people. To this end, Barloworld Equipment recently invested in Librestream's remote expert solution, Onsight. The solution will enable its field technicians to connect to remote expertise from any location and capture content for mentoring and later use. It will also provide technicians a safer way to perform inspections in the typically difficult field environments in which they operate.

"It was important to us to find an expert remote solution that provides the stability we need in the field while allowing our workforce to easily communicate cross-border. Not only will Onsight provide our teams with live remote mentoring, but also a way to quickly and efficiently get their job done for customers," said Barloworld Equipment's Charl Groenewald, Executive Head: Customer Fulfillment Services.

Barloworld Equipment is equipping its service teams with the Onsight Connect expert remote software as well as the Onsight rugged hardware products. A selection of these will be applied to the different service environments that teams typically operate in:

  • Onsight Cube , used for inspections at height or under vehicles, avoids field technicians moving into hazardous situations. Its thermal imaging capability also enables data collection on temperatures - mining equipment exhausts being an example.
  • Onsight Smartcam will have application in workshop situations, measuring and inspecting cracks or defects in equipment.
  • Onsight Hub, used exclusively with a field technician's borescope, assists with both inspections as well as mentoring of new technicians on the use of this equipment.

"Onsight is designed to empower workers by connecting them to their teams and the content they need to access," Kerry Thacher, CEO at Librestream said. "We are excited to be a part of Barloworld Equipment's innovative approach to enhance its customers' expectations and services."

About Barloworld Equipment
Barloworld Equipment is a division of Barloworld Limited, a multinational brand distribution company listed on the Johannesburg Stock Exchange.

Barloworld Equipment is the dealer for Cat earthmoving machines and Cat power systems in all its southern African territories - South Africa, Lesotho, Swaziland, Namibia, Botswana, Angola, Malawi, Mozambique, Zambia and the Democratic Republic of Congo's Katanga Province (in joint venture with Tractafric Equipment).

Additionally, Barloworld Equipment is the Cat dealer for Siberia and the Russian Far East.

Barloworld Equipment also operates in the United Kingdom and China.

Other Barloworld Group divisions comprise Barloworld Automotive and Barloworld Logistics.

Find more at www.barloworld-equipment.com and connect with us on LinkedInFacebook & Twitter.

About Librestream Technologies Inc.
Librestream develops digital transformation technology that improves service operations within the industrial sector. Deployed globally, the Onsight augmented reality service platform empowers workers to rapidly diagnose, inspect, and manage assets in even the most difficult field environments. The Onsight platform includes core AR capabilities including remote expert, digital work instructions and rich content access. Visit Librestream at www.librestream.com and connect with us on LinkedInFacebook & Twitter.

CONTACT INFORMATION

Press Contact:

Jacqui Janse van Rensburg
Communications Manager
Barloworld Equipment southern Africa
Tel: 011 301 4000
Email: JVRensburg1@barloworld-equipment.com

Marieke Wijtkamp
Vice President of Marketing & Client Services
Librestream Technologies Inc.
Tel: 204.487.0612 ext. 259
Email: marieke.wijtkamp@librestream.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fc0d5439-e2d2-4c25-af87-5cecf99a5812




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Librestream Technologies Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum